Enabled by POZ

We are developing proprietary drugs to treat neurological diseases and pain. We are advancing 4 wholly-owned IND product candidates. Our current discovery work is focused on unlocking the potential of cannabinoids across a range of CNS indications.

Our POZ platform partners are at the forefront in advancing LNP delivery technology to develop novel therapeutics in vaccine immunology, cancer immunoRX, and gene therapy.